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BY-NC-ND license (http://creativecomAbstract Background: Neonates are at a higher risk for bacterial meningitis than children of
other age groups. Although the mortality rates have decreased over the past few decades,
neonatal meningitis is still a severe disease with high morbidity. For bacterial meningitis, anti-
biotic therapy is the primary choice for management. However, neurologic complications often
cannot be averted;w40% of survivors exhibit neurological sequelae. Escherichia coli infection
is the common cause of neonatal meningitis. Previously, we have demonstrated that the re-
combinant loop 1e3, loop 2e3, and loop 2e4 fragments of OmpA protein can protect mice
from death after intracerebral E. coli infection. In this study, the protective effects of the re-
combinant OmpA protein fragments in E. coli intracerebral infections were investigated.
Methods: The effects of E. coli intracerebral infection on cytokine and chemokine expression
were determined. We also used various recombinant fragments of the OmpA protein to inves-
tigate the effects of these recombinant OmpA protein fragments on cytokine and chemokine
expression.
Results: In this study, we demonstrated that the expression of interleukin-17 and other cyto-
kines, chemokines, inducible nitric oxide synthase, and cyclooxygenase-2 are involved in the
inflammatory processes of intracerebral E. coli infection. We also demonstrated that specific
recombinant OmpA protein fragments (L1e3, L2e3, L2e4, and L3) can regulate cytokine, che-
mokine, nitric oxide synthase, and cyclooxygenase-2 expression and, subsequently, protect
mice from death caused by intracerebral infection of E. coli.dical Laboratory Science and Biotechnology, Taipei Medical University, Number 250, Wu-Hsing Street,
(H.-H. Wu).
.05.019
ociety of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC
mons.org/licenses/by-nc-nd/4.0/).
844 W.-S. Hsieh et al.Conclusion: This finding indicates the potential for developing a new therapeutic approach to
improve the prognosis of bacterial meningitis.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
A 29-year assessment of the evolving trends in neonatal and
childhood bacterial meningitis in Northern Taiwan revealed
that Escherichia coli and Streptococcus agalactiae (Group B
Streptococcus) are the two most common pathogens of
neonatal bacterial meningitis. In the past 5 years
(2008e2012), E. coli has surpassed Group B Streptococcus,
becoming the most common pathogen of neonatal menin-
gitis.1 E. coli strains with K1 capsular polysaccharide are
the most predominant strains associated with neonatal
bacterial meningitis.2 Several K1-associated components
including Fim H, K1 capsule, and outer membrane protein A
(OmpA) participate in brain microvascular endothelial cell
(BMEC) binding and invasion.3e7 OmpA is the determinant of
E. coli that mediates hostecell interactions and is crucial
for the invasion of E. coli K1 into macrophages and mono-
cytes.8 The OmpA protein is also the major component
enabling E. coli to adhere to and invade into BMECs and
astrocytes,5,9e11 and this binding is the most critical step in
E. coli K1 infection.11,12 In addition, OmpA is highly
conserved through the evolution of gram-negative bacilli.
This protein is the receptor for several bacteriophages,13e16
and is essential in bacterial conjugation.17e19 OmpA is
encoded using a 1038 bp open reading frame comprising a
21-amino-acid leader peptide and a mature 325-amino-acid
protein. The N-terminal membrane-anchoring domain of
OmpA is essential for effective folding and function. The N-
terminal domain forms an antiparallel b-barrel, containing
eight transmembrane b-strands, connected by three peri-
plasmic turns, and four surface-exposed hydrophilic loops.
The OmpA C-terminal domain interacts with the peptido-
glycan layer in the periplasm to maintain outer membrane
integrity.20 Purified N-terminal amino acids 1e171 of OmpA
bind directly to BMECs, whereas a derivative lacking all four
extracellular loops cannot.6 In addition, bacterial entry into
BMECs is governed by loops 1, 2, and 3.21 Specifically, the
short peptides corresponding to loops 1 and 2 can block the
OmpAþ E. coli invasion of BMECs.9 In addition, the OmpA
regions in loops 1, 2, and 4 resist serum bactericidal activity
through increased binding to a complement regulatory
protein, C4b-binding protein. The OmpA regions in loops 1
and 2 are responsible for E. coli survival in tissues and
blood, resulting in high-grade bacteremia, which is a pre-
requisite for the onset of meningitis.22
Inflammatory molecules such as cytokines, chemokines,
inducible nitric oxide synthase (NOS-2), and cyclooxygenase-
2 (COX-2) mediate a large amount of the neurologic damage
in central nervous system (CNS) infections.12,23 CD4þ T cells
differentiate into two subsets: CD4þ T helper 1 and T helper
2 cells. T helper 1 cells producing interleukin (IL)-2 andinterferon g (IFN-g) induce cell-mediated immunity,
whereas T helper 2 cells secreting IL-4, IL-5, and IL-13
stimulate humoral immunity.24 T helper 17 cells producing
IL-17 represent a subset distinct from other CD4þ Tcell
subsets; they provide protection against some infections and
are associated with the development of autoimmune dis-
eases. IL-17 functions as a proinflammatory cytokine; can
recruit granulocyte lineage, especially neutrophils25; and
functions synergistically with other inflammatory stimuli in
the CNS. IL-17 was required for the efficient eradication of
bacterial infection, stimulating granulopoiesis, neutrophil
recruitment, and proinflammatory molecules production.26
We previously reported that the recombinant full-
length, loop 1e3, loop 2e3, and loop 2e4 fragments of
the OmpA protein can protect mice from death after
intracerebral E. coli RS218 infection.11,27 In this study, the
protective effects of the recombinant OmpA protein frag-
ments in E. coli RS218 intracerebral infections were
investigated.Materials and methods
Chemicals, bacteria culture, and cell culture
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA), unless otherwise indicated. The recombinant
OmpA protein fragments (loops 1e2, 1e3, 1e4, 2e3, 2e4,
and 3e4) were expressed and purified as described in our
previous report.27 Briefly, the DNA fragments were ampli-
fied and ligated into the pET-21a expression vector (Nova-
gen, Darmstadt, Germany). The resultant plasmid was
transformed into E. coli BL21 (DE3). Protein expression was
induced and then purified using Ni2þ-charged sepharose
according to the manufacturer’s instructions (GE Health-
care Life Science, WI, USA). The recombinant OmpA protein
fragments loop 2 (amino acids 82e92) and loop 3 (amino
acids 128e134) were synthesized by Genomics Bioscience &
Technology Co., (Taipei, Taiwan). The E. coli strains used in
the present study were kindly provided by Dr. K.S. Kim
(Division of Pediatric Infectious Diseases, School of Medi-
cine, Johns Hopkins University, Baltimore, MD, USA); RS218
(O18:K1:H7) was isolated from the cerebrospinal fluid of a
neonate with meningitis. E91 is an RS218 mutant that lacks
the entire ompA gene.9 The bacteria were grown in a brain
heart infusion broth with appropriate antibiotics (Difco
Laboratories, Detroit, MI, USA). For infection experiments,
overnight cultures were expanded in the brain heart infu-
sion broth and incubated at 37C for 2e3 hours to the
midlog phase. The bacteria were centrifuged at 10,000g for
5 minutes and resuspended in a cell culture medium
Recombinant OmpA protein fragments 845without antibiotics. Cell Line C6, a rat glioma cell line
(ATCC CCL-107), was purchased from Bioresource Collec-
tion and Research Center, Hsinchu, Taiwan. Cells were
cultured in Ham F10 medium with 15% horse serum, 2.5%
fetal bovine serum, and 50 U/mL of penicillin-streptomycin
(all from Life Technologies, Gaithersburg, MD, USA).
Reverse transcription-polymerase chain reaction
and multiplex polymerase chain reaction
Confluent monolayer C6 cells were incubated with E. coli
RS218 at multiplicity of infection of 10 for 2 hours at 37C.
The cells were washed with culture medium three times
and incubated with culture medium containing 100 mg/mL
of gentamicin (Life Technologies) for 2 hours to kill the
extracellular bacteria. The cells were washed three times
with phosphate-buffered saline (PBS) and RNA was
extracted as described by the manufacturer with minor
modifications (Trizol reagent, Invitrogen). The extracted
RNA sample was immediately used for reverse transcription
(RT)-polymerase chain reaction (PCR), using a one-step RT-
PCR kit as described by the manufacturers (Qiagen,
Valencia, CA, USA). Then multiplex (M) PCR reactions were
set up using a MPCR Kit for Rat Sepsis Cytokines Set-2 as
described by the manufacturers (MBI, San Francisco, CA,
USA).
Animal experiments
C57BL/6 mice were obtained from the National Laboratory
Animal Center of Taiwan (Nangang, Taipei, Taiwan) and
maintained under pathogen-free conditions. This study was
conducted in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of
the Taipei Medical University, Taipei, Taiwan. The protocol
was approved by the Institutional Animal Care and Use
Committee of the Taipei Medical University (Approval IDs:
LAC-99-0009). All surgery was performed under pentobar-
bital sodium salt anesthesia, and every effort was made to
minimize suffering. In this experiment, male, 8e12-week-
old C57BL/6 mice were randomly distributed into groups.
The experimental protocol developed by Tsao et al12 was
followed to assess the survival of mice after intracerebral
bacterial administration. Each group containing five mice
were anesthetized with pentobarbital sodium salt (50 mg/
kg) with intraperitoneal injection; each brain was then
infected with E. coli RS218 (5  105 in 20 mL of PBS).
Concurrently, PBS (20 mL) was used as a negative control.
The mice were monitored for survival every 12 hours for 8
days. To investigate the effects of the recombinant OmpA
protein fragments on the survival of the C57BL/6 mice after
intracerebral E. coli RS218 administration, each brain was
infected with E. coli RS218 (5  105 in 20 mL of PBS) with
intracerebral injection in the presence of each recombi-
nant OmpA protein fragment (20 mg); the survival of these
mice was observed for up to 8 days after administration.
Groups of three C57BL/6 mice were infected with E. coli
RS218 with intracerebral injection in the presence or
absence of each recombinant OmpA protein fragment. The
mice were killed at various time points after the challenge.
For cytokine measurements, the brains were removed andstored at 80C and performed according to the manu-
facturer’s instructions of 23-plexpanel bead-based immu-
noassay kits (M60-009RDPD, Bio-Rad, Hercules, CA, USA).
For analyses, samples were thawed in 1.5 mL of cell lysis
buffer (Bio-Rad) containing a protease inhibitor cocktail
and 3 mL of a stock solution containing 500mM phenyl-
methylsulfonyl fluoride in dimethyl sulfoxide (Sigma, St.
Louis, MO, USA). Samples were homogenized by drawing
samples up and down through a 1 mL pipette tip (cut back
to a 2 mm opening) 20 times. Then, the samples were
centrifuged at 4500g for 15 minutes at 4C and supernatants
were collected. The total protein concentration was
determined using a Protein Assay Kit (Bio-Rad). All tissue
samples were diluted with cell lysis buffer as needed to a
final total protein concentration of 500 mg/mL. For Western
blotting, brains were homogenized with a protein extrac-
tion buffer (50 mmol/L of Tris HCl, pH 8.0, 150 mmol/L of
NaCl, 1% NP-40, and the protease inhibitor cocktails (Bio-
Rad), including 0.2 mmol/L of phenylmethanesulfonyl
fluoride, 20 mg/mL of aprotinin, and 20 mg/mL of leupeptin
and harvested for whole cell lysate. For remnant bacteria
detection, brains were aseptically removed and homoge-
nized with 3% gelatin in PBS. The samples were serially
diluted, and the colony forming unit for each sample was
determined on a blood agar plate.
Cytokine measurements
Brain homogenates were assayed for cytokines using 23-
plexpanel bead-based immunoassay kits [including IL-1a,
IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-
12 (p70), IL-13, IL-17, eotaxin, granulocyte-macrophage
colony-stimulating factor (GM-CSF), granulocyte colony-
stimulating factor, IFN-g, keratinocyte-derived cytokine
(KC), monocyte chemotactic protein (MCP)-1, macrophage
inflammatory protein-1a, macrophage inflammatory pro-
tein-1b, RANTES (regulated on activation, normal T cell
expressed and secreted), tumor necrosis factor (TNF)-a]
(M60-009RDPD, Bio-Rad), and performed according to the
manufacturer’s instructions. Cytokine data were analyzed
using Bio-Plex Manager 3.0 software (Bio-Rad).
Electrophoresis and immunoblotting
Electrophoresis was performed on 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Reagents for
odium dodecyl sulfate-polyacrylamide gel electrophoresis
were from Bio-Rad. After electrophoresis, proteins on the
gel were electrotransferred onto a polyvinylidene fluoride
(PVDF) membrane (Amersham Pharmacia Biotech, Buck-
inghamshire, UK). After transfer, the PVDF membranes
were blocked with blocking solution containing 5% skim milk
in TBST (10 mmol/L Tris, pH7.5, 100 mmol/L NaCl, and 0.1%
Tween 20) for 1 hour at room temperature. Antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) unless otherwise indicated. The PVDF membrane was
incubated with a solution containing rabbit anti-NOS-2
antibody (1:200), rabbit anti-COX-2 antibody (1:200), or
goat antiactin antibody (1:200) in the blocking buffer for 2
hours. After washing, the PVDF membrane was incubated
with peroxidase-linked secondary antibody (1:2000) for 1
Figure 1. Intracerebral infection of Escherichia coli RS218 induced the expression of various cytokines and chemokines in vivo.
Groups of three mice were anesthetized and challenged using intracerebral injection with 5  105 bacteria alone or a premixture of
20 mg of each recombinant OmpA protein fragment: L1e2, L1e3, L1e4, L2e3, L2e4, L3e4, L2, L3, and L2 þ L3. The brains were
collected after 48 hours of treatment. Individual cytokines and chemokines were quantified. Paired Student t tests were used to
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Figure 2. Cytokine expression in astrocytes induced by
Recombinant OmpA protein fragments 847hour. Finally, the PVDF membrane was developed using a
chemiluminescence kit (Amersham).
Statistical analysis
The results were expressed as the mean  standard devi-
ation of independent experiments. Quantitative variables
were analyzed using the paired Student t test. The results
were considered significant when the calculated p < 0.05.Escherichia coli RS218 infection. When the C6 cells had been
infected with E. coli RS218 for 2 hours, the total mRNA of the
C6 cells was extracted, and the cytokine expression was then
determined using reverse transcriptase-polymerase chain re-
action and multiplex polymerase chain reaction. The expres-
sion of interluekin-6, tumor necrosis factor-a, and interluekin-
1b mRNA was induced in C6 cells infected by E. coli RS218.
Glyceraldehyde 3-phosphate dehydrogenase was used as a
loading control. GADPH Z glyceraldehyde 3-phosphate dehy-
drogenase; IL Z interleukin; TNF Z tumor necrosis factor.Results
Intracerebral injection of E. coli RS218 induced the
expression of IL-17 and other cytokines and
chemokines; recombinant OmpA protein fragments
regulated this expression
Inflammatory molecules such as cytokines mediate a large
amount of the neurologic damage in CNS infections.12,23
The effects of E. coli RS218 intracerebral infection on
cytokine and chemokine expression were determined. We
challenged the mice by using intracerebral injection to
avoid interference with the bloodebrain barrier (BBB) ac-
cording to the protocol presented by Tsao et al.12 Groups of
three C57BL/6 mice were anesthetized and then infected
with an intracerebral injection of E. coli RS218 or E91 (an
RS218 mutant that lacks the entire ompA gene) for 24
hours. The brains were removed, and homogenates were
assayed for 23 cytokines and chemokines. The results
showed that intracerebral injection of E. coli RS218 but not
E91 induced the expression of IL-17, IL-6, TNF-a, IL-1b, GM-
CSF, IL-4, IL-5, IL-13, and chemotactic chemokines, namely
MCP-1 (CCL2), RANTES (CCL5), and KC (CXCL1; GROa)
(Figure 1). In addition, we determined whether the pres-
ence of recombinant OmpA protein fragments regulated
cytokine or chemokine expression in E. coli meningitis.
Groups of three C57BL/6 mice were challenged by intra-
cerebrally injecting them with a mixture of E. coli RS218
and 20 mg of each recombinant OmpA protein fragment
(loops 1e2, 1e3, 1e4, 2e3, 2e4, 3e4, L2, L3, and L2 þ L3),
and the cytokine expression was measured. Individual re-
combinant OmpA protein fragments exerted various effects
on the cytokine and chemokine expression (Figure 1). The
recombinant OmpA protein fragments L1e3, L2e3, L2e4,
and L3 greatly inhibited the expression of IL-17, IL-6, TNF-
a, IL-1b, GM-CSF, IL-4, IL-5, IL-13, and the chemotactic
chemokines MCP-1 (CCL2), RANTES (CCL5), and KC (CXCL1;
GROa). By contrast, the recombinant OmpA protein frag-
ments L1e3, L2e3, L2e4, and L3 upregulated the expres-
sion of IL-10, an immunosuppressive cytokine.
In a previous study, we identified that OmpA-mediated
E. coli infection activates astrocytes in vitro and in the
mouse brain.11 In addition, cytokine induction after E. coli
RS218 (OmpAþ) infection in astrocytes was determined
using RT-PCR and MPCR. We employed rat glioma C6compare the RS218 results (*p < 0.05; **p < 0.001). GM-CSFZ granu
KC Z mouse keratinocyte-derived cytokine; MCP Z monocyte checells28,29 as an in vitro system of astrocytes. After the cells
had been infected with E. coli RS218 for 2 hours, the
expression of IL-6, TNF-a, and IL-1b mRNA was induced at
individual time intervals (Figure 2).
Recombinant OmpA protein fragments inhibited E.
coli-RS218-infection-induced iNOS-2 and COX-2
expression
The inflammatory molecules NOS-2 and COX-2 play crucial
roles in the neurologic damage of CNS infections12,23; the
expression of NOS-2 and COX-2 after E. coli RS218 infection
was examined. Groups containing three mice each were
infected with bacteria through intracerebral injection. At
24 hours postchallenge, the brains were removed and
analyzed for NOS-2 and COX-2 expression by conducting
immunoblotting. As shown in Figures 3A and 3B, NOS-2 and
COX-2 expression was induced after infection with E. coli
RS218. In addition, whether the presence of recombinant
OmpA protein fragments inhibited NOS-2 and COX-2
expression in the mouse brains was determined. Addi-
tional groups of mice were challenged by intracerebrally
injecting them with a mixture of E. coli RS218 and 20 mg of
each recombinant OmpA protein fragment (loops 1e2, 1e3,
1e4, 2e3, 2e4, 3e4, L2, L3, and L2 þ L3); NOS-2 and COX-2
expression was then analyzed by performing immunoblot-
ting. The results showed that the NOS-2 and COX-2
expression in the brain was inhibited by the recombinant
OmpA protein fragments L1e3, L2e3, L2e4, L2, L3, and
L2 þ L3 (Figures 3A and 3B). Taken together, these data
indicated that specific recombinant OmpA protein frag-
ments (L1e3, L2e3, L2e4, and L3) protected the mice from
the expression of NOS-2, COX-2, cytokines, and chemokines
in the brain. These effects may have protected the mice
from severe neuronal damage.locyte-macrophage colony-stimulating factor; ILZ interleukin;
moattractant protein; TNF Z tumor necrosis factor.
Figure 3. Specific recombinant OmpA protein fragments inhibited the nitric oxide synthase-2 and cyclooxygenase-2 expression
induced by Escherichia coli RS218 infection in vivo. Groups of three C57BL/6 mice each were anesthetized and challenged by
intracerebrally injecting them with 5  105 bacteria alone or a premixture of 20 mg of each recombinant OmpA protein fragment:
L1e2, L1e3, L1e4, L2e3, L2e4, L3e4, L2, L3, and L2 þ L3. The mice were sacrificed 24 hours postinfection. Western analysis of
whole brain lysates was performed to detect nitric oxide synthase-2 (A) or cyclooxygenase-2 (B) and actin. COX-
2 Z cyclooxygenase-2; NOS-2 Z nitric oxide synthase-2.
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C57BL/6 mice from death induced by E. coli
infection
Groups containing five C57BL/6 mice were anesthetized
and then infected through intracerebral injection of E. coli
RS218, and the survival of these mice was assessed for 8
days. The mice died within 48 hours of intracerebral in-
jection of the OmpAþ E. coli strain RS218. Next, we
determined whether the presence of recombinant OmpA
protein fragments protected the mice from E. coli RS218
infection. Groups of five C57BL/6 mice were challenged by
intracerebrally injecting them with a mixture of E. coliFigure 4. Survival of C57BL/6 mice after infection with
Escherichia coli RS218. Groups of five C57BL/6 mice were
anesthetized and challenged by intracerebrally injecting them
with 5  105 bacteria alone or a premixture of 20 mg of each
recombinant OmpA protein fragment: L1e2, L1e3, L1e4,
L2e3, L2e4, L3e4, L2, L3, and L2 þ L3. The mice were
monitored for survival for up to 8 days.RS218 and 20 mg of each recombinant OmpA protein frag-
ment (loops 1e2, 1e3, 1e4, 2e3, 2e4, 3e4, L2, L3, and
L2 þ L3) and assessed for 8 days. As shown in Figure 4, 50%
of the mice injected with E. coli RS218 and L1e3, 60% of the
mice injected with E. coli RS218 and L2e3, 50% of the mice
injected with E. coli RS218 þ L2e4, 50% of the mice
injected with E. coli RS218 and L3, and 38% of the mice with
E. coli RS218, L2, and L3 survived until Day 8 postinfection.
These results suggested that the recombinant OmpA pro-
tein fragments L1e3, L2e3, L2e4, and L3 significantly
prolonged the survival of the C57BL/6 mice after intrace-
rebral E. coli RS218 infection (p < 0.05).Figure 5. Remnant bacteria in the brain after Escherichia
coli RS218 infection. Groups of three mice were anesthetized
and challenged by intracerebrally injecting them with 5  105
bacteria alone or a premixture of 20 mg of each recombinant
OmpA protein fragment: L1e2, L1e3, L1e4, L2e3, L2e4,
L3e4, L2, L3, and L2 þ L3. The brains were collected at various
time points after treatment. Remnant bacteria in the brains
were quantified.
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the C57BL/6 mice from infection-induced death
correlating with bacterial clearance
We examined the remnant bacteria in the brain after E. coli
RS218 infection, which gradually increased to
(8.5  0.3)  107 at 36 hours postinfection (Figure 5); the
mice died within 48 hours of intracerebral E. coli RS218
infection. In addition, for mice infected with the E. coli
RS218 premixed with the recombinant OmpA protein frag-
ments L1e2, L1e4, and L3e4, the remnant bacteria in the
brain gradually increased to (8.6  0.1)  107,
(9.2  0.0)  107, and (8.8  0.1)  107, respectively, at 60
hours postinfection (Figure 5). Similarly, for the mice
infected with E. coli RS218 premixed with the recombinant
OmpA protein fragment L2, the remnant bacteria in the
brain gradually increased to (8.7  0.1)  107 at 48 hours
postinfection. Those mice died within 72 hours after bac-
terial infection. By contrast, the remnant bacteria in the
brains infected with E. coli RS218 premixed with the re-
combinant OmpA protein fragments L1e3, L2e3, L2e4, L3,
and L2 þ L3 decreased after infection and were undetect-
able at 48 hours after infection (Figure 5). The results
indicated that these specific recombinant OmpA protein
fragments protected the mice from E. coli infection, and
this protection correlated with bacterial clearance.
Discussion
A neuronal injury associated with bacterial infection of the
CNS involves multiple microbial and host factors. Severe
bacteremia and invasion through BMECs are the deter-
mining factors contributing to CNS infection.30 Despite the
availability of advanced antibiotic therapy and patient care
for bacterial meningitis; it is still associated with a rela-
tively high morbidity and mortality. Nearly 40% of surviving
patients undergo various neurological complications.1,31,32
These findings indicate that a new therapeutic approach
must be developed to improve the prognosis of bacterial
meningitis.
Inflammation in the CNS is controlled by various cyto-
kines. In the present study, intracerebral injection of E. coli
RS218 induced the expression of IL-17, IL-6, TNF-a, IL-1b,
GM-CSF, IL-4, IL-5, IL-13, and the chemotactic chemokines
MCP-1 (CCL2), RANTES (CCL5), and KC (CXCL1; GROa)
(Figure 1). In the CNS, astrocytes and microglia express IL-
17 receptors, whereas neurons do not.33 IL-17 was shown to
stimulate the IL-6 and IL-8 released by glioblastoma cells of
the CNS.34 Kawanokuchi et al33 showed that treatment with
IL-17 upregulated the microglial production of IL-6,
macrophage inflammatory protein-2, adhesion molecules,
neurotrophic factors, and NO.33 In this study, we demon-
strated that E. coli RS218 infection induces the expression
of IL-1b, IL-6, and TNF-a mRNA in astrocytes (Figure 2).
The chemokine MCP-1 (CCL2) was established as a
mediator of inflammation within and outside the CNS and as
a stimulator of the extravasation of mononuclear leuko-
cytes into the CNS.35 Astrocyte-derived MCP-1 regulates
BBB integrity and leukocyte penetration of the CNS paren-
chyma, whereas endothelial-derived MCP-1 affects leuko-
cyte transendothelial migration.36 Trajkovic et al37 showedthat IL-17 synergized with IFN-g, IL-1, and TNF-a, thus
activating NOS-2 and subsequent NO production in rodent
astrocytes. NOS-2 is produced in the CNS in response to
inflammation, possibly by astrocytes and microglia as well
as by macrophages that invade the CNS. In this study, we
showed that intracerebral injection of E. coli RS218
induced the expression of NOS-2 and COX-2 (Figures 3A and
3B). Inflammatory processes resulted in the destruction of
the BBB, neuron damage, and finally, death in C57BL/6
mice. Our data demonstrated that specific recombinant
OmpA protein fragments (L1e3, L2e3, L2e4, and L3) can
inhibit the expression of cytokines, chemokines, NOS-2, and
COX-2 in vivo. The same recombinant OmpA protein frag-
ments also upregulate the expression of IL-10, an immu-
nosuppressive cytokine, thus preventing subsequent
inflammatory processes. The counteraction between the
proinflammatory cytokines and protective cytokines de-
termines the final outcome in organ and tissues. We have
previously demonstrated that the recombinant full-length,
L1e3, L2e3, and L2e4 fragments of the OmpA protein
can protect mice from death after intracerebral E. coli
infection.11,27 Furthermore, based on the results of the
present study, we propose that L2e3 and L3 fragments of
the OmpA protein may act as the shorter protective pep-
tides that can regulate the expression of cytokines, che-
mokines, NOS-2, and COX-2 and, subsequently, protect
mice from death caused by the intracerebral injection of E.
coli RS218. In bacterial meningitis, although antibiotic
therapy is the primary choice for management, neurolog-
ical complications can seldom be averted. Thus, the
possible protective effects of recombinant OmpA protein
fragments on patients with bacterial meningitis as well as
the routes for administering these fragments require
further investigation.Conflicts of interest
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